Northwest Biotherapeutics, Inc. (NWBO)
USD 0.27
(1.89%)
USD 0.27
(1.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -55.33 Million USD | 18.09% |
| 2022 | -97.41 Million USD | -24.42% |
| 2021 | 184.72 Million USD | 38.78% |
| 2020 | -520.85 Million USD | -213.8% |
| 2019 | -17.81 Million USD | 36.82% |
| 2018 | -24.62 Million USD | 23.12% |
| 2017 | -67.15 Million USD | 33.3% |
| 2016 | -76.2 Million USD | 32.85% |
| 2015 | -110.53 Million USD | -5.16% |
| 2014 | -134.62 Million USD | -81.62% |
| 2013 | -64.9 Million USD | -20.26% |
| 2012 | -51.82 Million USD | -93.63% |
| 2011 | -25.17 Million USD | -164.44% |
| 2010 | -15.35 Million USD | -14.53% |
| 2009 | -15.76 Million USD | 55.88% |
| 2008 | -21.59 Million USD | -108.45% |
| 2007 | -10.18 Million USD | 8.28% |
| 2006 | -5.96 Million USD | -221.63% |
| 2005 | -3.45 Million USD | 17.55% |
| 2004 | -4.68 Million USD | 30.26% |
| 2003 | -6.26 Million USD | 63.05% |
| 2002 | -15.17 Million USD | -82.2% |
| 2001 | -8.92 Million USD | -584.63% |
| 2000 | -1.3 Million USD | 76.6% |
| 1999 | -5.57 Million USD | -16.28% |
| 1998 | -4.79 Million USD | -83.52% |
| 1997 | -2.61 Million USD | -112.2% |
| 1996 | -1.23 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -15.23 Million USD | 5.61% |
| 2024 Q2 | -16.94 Million USD | 3.79% |
| 2023 Q2 | -13.05 Million USD | -3.51% |
| 2023 FY | - USD | 18.09% |
| 2023 Q1 | -12.61 Million USD | 28.99% |
| 2023 Q4 | -14.72 Million USD | -6.48% |
| 2023 Q3 | -13.82 Million USD | -5.88% |
| 2022 Q4 | -17.76 Million USD | -16.52% |
| 2022 Q1 | -12.12 Million USD | -11.57% |
| 2022 FY | - USD | -24.42% |
| 2022 Q3 | -15.24 Million USD | 25.68% |
| 2022 Q2 | -20.51 Million USD | -69.17% |
| 2021 Q3 | -10.21 Million USD | 16.81% |
| 2021 Q4 | -10.86 Million USD | -6.44% |
| 2021 Q1 | -19.4 Million USD | 16.4% |
| 2021 Q2 | -12.27 Million USD | 36.76% |
| 2021 FY | - USD | 38.78% |
| 2020 FY | - USD | -213.8% |
| 2020 Q3 | -47.77 Million USD | -549.9% |
| 2020 Q2 | -7.35 Million USD | 3.77% |
| 2020 Q1 | -7.63 Million USD | -15.67% |
| 2020 Q4 | -23.21 Million USD | 51.4% |
| 2019 Q2 | -6.43 Million USD | 16.84% |
| 2019 FY | - USD | 36.82% |
| 2019 Q4 | -6.6 Million USD | -5.92% |
| 2019 Q3 | -6.23 Million USD | 3.11% |
| 2019 Q1 | -7.73 Million USD | -28.11% |
| 2018 FY | - USD | 23.12% |
| 2018 Q1 | -8.45 Million USD | 52.19% |
| 2018 Q2 | -19.99 Million USD | -136.62% |
| 2018 Q3 | -8.97 Million USD | 55.1% |
| 2018 Q4 | -6.04 Million USD | 32.72% |
| 2017 Q3 | -16.38 Million USD | -54.31% |
| 2017 FY | - USD | 33.3% |
| 2017 Q4 | -17.67 Million USD | -7.87% |
| 2017 Q2 | -10.62 Million USD | 10.36% |
| 2017 Q1 | -11.84 Million USD | 53.39% |
| 2016 Q3 | -26.91 Million USD | -79.98% |
| 2016 Q1 | -17.46 Million USD | 66.0% |
| 2016 Q4 | -25.41 Million USD | 5.58% |
| 2016 Q2 | -14.95 Million USD | 14.37% |
| 2016 FY | - USD | 32.85% |
| 2015 Q1 | -22.82 Million USD | 12.75% |
| 2015 FY | - USD | -5.16% |
| 2015 Q3 | -13.18 Million USD | 66.06% |
| 2015 Q4 | -51.37 Million USD | -289.67% |
| 2015 Q2 | -38.84 Million USD | -70.15% |
| 2014 Q2 | -30.51 Million USD | -5.47% |
| 2014 Q3 | -34.42 Million USD | -12.83% |
| 2014 Q4 | -26.16 Million USD | 24.0% |
| 2014 Q1 | -28.93 Million USD | -62.08% |
| 2014 FY | - USD | -81.62% |
| 2013 Q3 | -22.9 Million USD | -100.86% |
| 2013 Q1 | -13.94 Million USD | 47.83% |
| 2013 FY | - USD | -20.26% |
| 2013 Q4 | -17.84 Million USD | 22.06% |
| 2013 Q2 | -11.4 Million USD | 18.22% |
| 2012 Q3 | -13.73 Million USD | -57.25% |
| 2012 Q1 | -6.6 Million USD | -714.71% |
| 2012 FY | - USD | -93.63% |
| 2012 Q4 | -26.72 Million USD | -94.53% |
| 2012 Q2 | -8.73 Million USD | -32.31% |
| 2011 Q2 | -7.28 Million USD | -10.52% |
| 2011 FY | - USD | -164.44% |
| 2011 Q4 | 1.07 Million USD | 106.9% |
| 2011 Q3 | -15.57 Million USD | -113.64% |
| 2011 Q1 | -6.59 Million USD | -13.82% |
| 2010 Q1 | -3 Million USD | 13.55% |
| 2010 Q2 | 1.79 Million USD | 159.72% |
| 2010 Q3 | -2.61 Million USD | -245.76% |
| 2010 FY | - USD | -14.53% |
| 2010 Q4 | -5.79 Million USD | -121.57% |
| 2009 Q2 | -2.87 Million USD | 13.24% |
| 2009 Q3 | 806 Thousand USD | 128.02% |
| 2009 Q4 | -3.47 Million USD | -531.14% |
| 2009 FY | - USD | 55.88% |
| 2009 Q1 | -3.31 Million USD | 22.49% |
| 2008 Q3 | -5.29 Million USD | 11.67% |
| 2008 Q2 | -5.99 Million USD | -5.88% |
| 2008 Q1 | -5.66 Million USD | 18.65% |
| 2008 Q4 | -4.27 Million USD | 19.25% |
| 2008 FY | - USD | -108.45% |
| 2007 Q1 | -1.75 Million USD | -13.29% |
| 2007 Q3 | -3.06 Million USD | -292.16% |
| 2007 FY | - USD | 8.28% |
| 2007 Q2 | 1.59 Million USD | 190.77% |
| 2007 Q4 | -6.96 Million USD | -127.36% |
| 2006 Q4 | -1.55 Million USD | -32.14% |
| 2006 Q1 | 2.03 Million USD | 748.56% |
| 2006 Q3 | -1.17 Million USD | 88.72% |
| 2006 FY | - USD | -221.63% |
| 2006 Q2 | -10.4 Million USD | -612.32% |
| 2005 FY | - USD | 17.55% |
| 2005 Q4 | -313 Thousand USD | 72.74% |
| 2005 Q3 | -1.14 Million USD | -15.96% |
| 2005 Q2 | -990 Thousand USD | 1.0% |
| 2005 Q1 | -1 Million USD | -54.8% |
| 2004 FY | - USD | 30.26% |
| 2004 Q4 | -646 Thousand USD | 73.5% |
| 2004 Q3 | -2.43 Million USD | -373.4% |
| 2004 Q2 | -515 Thousand USD | 25.47% |
| 2004 Q1 | -691 Thousand USD | 7.62% |
| 2003 Q1 | -1.5 Million USD | 66.05% |
| 2003 FY | - USD | 63.05% |
| 2003 Q4 | -748 Thousand USD | 34.84% |
| 2003 Q3 | -1.14 Million USD | 55.95% |
| 2003 Q2 | -2.86 Million USD | -73.16% |
| 2002 Q3 | -3.37 Million USD | 21.82% |
| 2002 Q1 | -3.03 Million USD | 70.04% |
| 2002 FY | - USD | -82.2% |
| 2002 Q4 | -4.43 Million USD | -31.23% |
| 2002 Q2 | -4.32 Million USD | -42.15% |
| 2001 Q4 | -10.14 Million USD | -41219.64% |
| 2001 FY | - USD | -584.63% |
| 2001 Q3 | 24.67 Thousand USD | 0.0% |
| 2001 Q1 | 24.67 Thousand USD | 100.37% |
| 2001 Q2 | 24.67 Thousand USD | 0.0% |
| 2000 Q4 | -6.64 Million USD | -18.15% |
| 2000 FY | - USD | 76.6% |
| 2000 Q3 | -5.62 Million USD | 0.0% |
| 1999 FY | - USD | -16.28% |
| 1998 FY | - USD | -83.52% |
| 1997 FY | - USD | -112.2% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 22.097% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -833.376% |
| SQZ Biotechnologies Company | -64.14 Million USD | 13.723% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -218.59% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 158.847% |
| Mesoblast Limited | -62.38 Million USD | 11.301% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3502.685% |
| Genus plc | 73.7 Million USD | 175.087% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -737.009% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1460.164% |
| Marizyme, Inc. | -34.28 Million USD | -61.425% |
| ContraFect Corporation | -64.99 Million USD | 14.862% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -530.86% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1122.638% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3847.688% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1992.648% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2281.381% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -10582.256% |
| Accustem Sciences Inc. | -3.74 Million USD | -1377.117% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -14.747% |
| EV Biologics, Inc. | -1.26 Million USD | -4267.264% |
| Q BioMed Inc. | -617.62 Thousand USD | -8859.924% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1649.244% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -8650.549% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2322.38% |
| Biomind Labs Inc. | -1.03 Million USD | -5249.094% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 660.281% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -672.753% |
| Skye Bioscience, Inc. | -13.54 Million USD | -308.48% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3620.489% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -221256.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1324.677% |
| IMV Inc. | -35.52 Million USD | -55.782% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -248.708% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2111.824% |
| GB Sciences, Inc. | -1.41 Million USD | -3797.428% |
| Alpha Cognition Inc. | -9.7 Million USD | -470.176% |
| HST Global, Inc. | -5303.00 USD | -1043441.392% |
| CSL Limited | 4.78 Billion USD | 101.156% |
| Halberd Corporation | -74.27 Thousand USD | -74401.541% |
| Enzolytics Inc. | -2.12 Million USD | -2507.834% |
| Resverlogix Corp. | -11.74 Million USD | -371.291% |
| Affymax, Inc. | -14.29 Million USD | -287.121% |
| SYBLEU INC | -141.57 Thousand USD | -38989.22% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1706.683% |
| argenx SE | -216.02 Million USD | 74.383% |
| MetaStat, Inc. | - USD | Infinity% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 4647.165% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -3591.959% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 14707.332% |
| AVAX Technologies, Inc. | -6.11 Million USD | -805.32% |
| Zenith Capital Corp. | -8.6 Million USD | -543.028% |
| Genscript Biotech Corporation | -248.71 Million USD | 77.75% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -317556.851% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2162.002% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -31338.262% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -39.615% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1813.304% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -5188.958% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 823107.139% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -3062.23% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2780.873% |
| BioStem Technologies, Inc. | -7.55 Million USD | -632.613% |
| ONE Bio Corp. | 13.61 Million USD | 506.515% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -30459.176% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2590.277% |
| Agentix Corp. | -1.37 Million USD | -3934.172% |
| LadRx Corporation | 412.28 Thousand USD | 13522.576% |
| Cell Source, Inc. | -4.27 Million USD | -1195.229% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -14969.672% |
| Regen BioPharma, Inc. | 1.46 Million USD | 3874.943% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -5806.298% |
| NovAccess Global Inc. | -1.03 Million USD | -5247.812% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 725.031% |
| Itoco Inc. | -1.86 Million USD | -2860.896% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -14477.472% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -4858.692% |
| Kadimastem Ltd | -2.62 Million USD | -2008.65% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -23039.87% |
| CytoDyn Inc. | -18.02 Million USD | -206.944% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -69923.662% |
| Mobile Lads Corp. | -2.24 Million USD | -2369.213% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -452422.692% |
| Qrons Inc. | -40.08 Thousand USD | -137967.912% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -11294.175% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 10592.138% |
| Rebus Holdings, Inc. | -951 Thousand USD | -5719.033% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5110.78% |
| International Stem Cell Corporation | 202 Thousand USD | 27495.545% |
| Bioxytran, Inc. | -3.82 Million USD | -1348.609% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -105027.28% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2147.788% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -54.281% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -122875.556% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1921.147% |
| Neutra Corp. | -181.24 Thousand USD | -30432.367% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -174.513% |
| PureTech Health plc | -11.62 Million USD | -375.953% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -174.531% |
| IXICO plc | -707 Thousand USD | -7727.298% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -620.091% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -14.464% |
| CSL Limited | 4.73 Billion USD | 101.169% |
| Cellectis S.A. | -92.63 Million USD | 40.262% |